Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

Effective combination therapies to improve the efficacy of BET inhibitors are currently under investigation. Here, the authors examine palbociclib and paclitaxel as two promising candidates for combination therapies with BET inhibition in breast cancer and investigate the dynamics of resistance to t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jennifer Y. Ge, Shaokun Shu, Mijung Kwon, Bojana Jovanović, Katherine Murphy, Anushree Gulvady, Anne Fassl, Anne Trinh, Yanan Kuang, Grace A. Heavey, Adrienne Luoma, Cloud Paweletz, Aaron R. Thorner, Kai W. Wucherpfennig, Jun Qi, Myles Brown, Piotr Sicinski, Thomas O. McDonald, David Pellman, Franziska Michor, Kornelia Polyak
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/c6750e9707894301940edb49bbf81051
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6750e9707894301940edb49bbf81051
record_format	dspace
spelling	oai:doaj.org-article:c6750e9707894301940edb49bbf810512021-12-02T17:02:20ZAcquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer10.1038/s41467-020-16170-32041-1723https://doaj.org/article/c6750e9707894301940edb49bbf810512020-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-16170-3https://doaj.org/toc/2041-1723Effective combination therapies to improve the efficacy of BET inhibitors are currently under investigation. Here, the authors examine palbociclib and paclitaxel as two promising candidates for combination therapies with BET inhibition in breast cancer and investigate the dynamics of resistance to these combinations through DNA barcoding and mathematical modelling.Jennifer Y. GeShaokun ShuMijung KwonBojana JovanovićKatherine MurphyAnushree GulvadyAnne FasslAnne TrinhYanan KuangGrace A. HeaveyAdrienne LuomaCloud PaweletzAaron R. ThornerKai W. WucherpfennigJun QiMyles BrownPiotr SicinskiThomas O. McDonaldDavid PellmanFranziska MichorKornelia PolyakNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Jennifer Y. Ge Shaokun Shu Mijung Kwon Bojana Jovanović Katherine Murphy Anushree Gulvady Anne Fassl Anne Trinh Yanan Kuang Grace A. Heavey Adrienne Luoma Cloud Paweletz Aaron R. Thorner Kai W. Wucherpfennig Jun Qi Myles Brown Piotr Sicinski Thomas O. McDonald David Pellman Franziska Michor Kornelia Polyak Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
description	Effective combination therapies to improve the efficacy of BET inhibitors are currently under investigation. Here, the authors examine palbociclib and paclitaxel as two promising candidates for combination therapies with BET inhibition in breast cancer and investigate the dynamics of resistance to these combinations through DNA barcoding and mathematical modelling.
format	article
author	Jennifer Y. Ge Shaokun Shu Mijung Kwon Bojana Jovanović Katherine Murphy Anushree Gulvady Anne Fassl Anne Trinh Yanan Kuang Grace A. Heavey Adrienne Luoma Cloud Paweletz Aaron R. Thorner Kai W. Wucherpfennig Jun Qi Myles Brown Piotr Sicinski Thomas O. McDonald David Pellman Franziska Michor Kornelia Polyak
author_facet	Jennifer Y. Ge Shaokun Shu Mijung Kwon Bojana Jovanović Katherine Murphy Anushree Gulvady Anne Fassl Anne Trinh Yanan Kuang Grace A. Heavey Adrienne Luoma Cloud Paweletz Aaron R. Thorner Kai W. Wucherpfennig Jun Qi Myles Brown Piotr Sicinski Thomas O. McDonald David Pellman Franziska Michor Kornelia Polyak
author_sort	Jennifer Y. Ge
title	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
title_short	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
title_full	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
title_fullStr	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
title_full_unstemmed	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
title_sort	acquired resistance to combined bet and cdk4/6 inhibition in triple-negative breast cancer
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/c6750e9707894301940edb49bbf81051
work_keys_str_mv	AT jenniferyge acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT shaokunshu acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT mijungkwon acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT bojanajovanovic acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT katherinemurphy acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT anushreegulvady acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT annefassl acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT annetrinh acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT yanankuang acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT graceaheavey acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT adrienneluoma acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT cloudpaweletz acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT aaronrthorner acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT kaiwwucherpfennig acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT junqi acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT mylesbrown acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT piotrsicinski acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT thomasomcdonald acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT davidpellman acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT franziskamichor acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer AT korneliapolyak acquiredresistancetocombinedbetandcdk46inhibitionintriplenegativebreastcancer
_version_	1718381932543213568

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

Ejemplares similares